The radiotoxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes

J Nucl Med. 2004 Apr;45(4):608-11.

Abstract

We investigated cytologic radiation damage in thyroid cancer after (131)I therapy using micronucleus assay (MNA) of B lymphocytes exclusively, as opposed to our previous study in which MNA of all lymphocyte subsets was used.

Methods: We studied 22 thyroid cancer patients treated with 3.7 GBq of (131)I. Peripheral lymphocytes were harvested, and B lymphocytes were isolated by an immunomagnetic method and assayed for the frequency of micronuclei.

Results: The frequency of micronuclei among B cells after (131)I therapy was significantly increased relative to that in untreated control subjects, and the (131)I-induced increase in micronuclei frequency among B cells was significantly greater than that among all lymphocytes.

Conclusion: Compared with the MNA of all lymphocytes, the MNA among specifically B cells may more sensitively detect cytologic radiation damage associated with (131)I therapy of thyroid cancer.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • B-Lymphocytes / pathology
  • B-Lymphocytes / radiation effects*
  • Chromosome Aberrations
  • Chromosomes / radiation effects
  • Female
  • Humans
  • Iodine Radioisotopes / adverse effects*
  • Iodine Radioisotopes / therapeutic use*
  • Male
  • Micronucleus Tests
  • Middle Aged
  • Radiation Injuries / etiology*
  • Radiation Injuries / genetics*
  • Radiopharmaceuticals / adverse effects
  • Radiopharmaceuticals / therapeutic use
  • Radiotherapy / adverse effects
  • Thyroid Gland / pathology
  • Thyroid Gland / radiation effects*
  • Thyroid Neoplasms / blood
  • Thyroid Neoplasms / pathology
  • Thyroid Neoplasms / radiotherapy*

Substances

  • Iodine Radioisotopes
  • Radiopharmaceuticals